ÃâÒßѧÊÔÌâ
$O|J8; "v Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£©
Q=hf,/N 1. Fas(CD95)/FasL
S].=gR0: 2. common chain of cytokine receptor
C+/D!ZH%P 3 . TCR/CD3 complex
4BSSJ@
z 4. negaive selection of thymocytes
;dq AmBG{8 5. artificial active immune
cB5|%@$I 6. anti-idiotypic
;jb+x5t 7. IgSF
lW F=bz0 8. Integrin
ti`
R 9. chemokine
@C),-TM 10. B7/CD28
<fY<.X ¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£©
Dim,HPx]d 1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԲÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹ÔµÄ¹ý³Ì¡£
a^+b(&;k 2. ±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã¡£
VK9I#
3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ 4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô»òÖ×ÁöÏà¹Ø¿¹Ô,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆÊµÑé·½°¸¿Ë¡´Ë»ùÒò¡£
l\l\T<wa, 5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½
F8 4LMk?U
c9e
}P 1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô¡£
1a{~B# µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ
h~$Q\WCm# Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£©
lyzMKla" 1. B7/CD28
hk"^3d ! 2. Th1 subset
i3k ',8 3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£©
ZiDmx-X 4. antibody affinity maturation
>gDsjHQ6; 5. AP-1
_:om(gL 6. single chain variable fragment£¨ScFv£©
whP>'9t.w 7. NK cell receptor
Z2B59,I 8. Zinkernagel-Doherty phenomenon
~AuvB4xe~ 9. Ig fold
IsO'aFK)ln 10. CD40/CD40L
M3 8,SH< ¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£©
)|/t}|DIx 1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØÏµ¡£
Ov%9S/d 2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿
h Mw}[6m 3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹ØÏµ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿
C78d29 Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩
O*oL(dk*8L 1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô¡¢ÁܰÍϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£
cd}TDd(H% 2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£
d
QA J`9B 3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æ×¨Òµ£©¡£
I_xJ[ALdm Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ
-'k<2 "z £¨ÃâÒßѧרҵºÍרҵ»ù´¡£©
7w)#[^ Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£©
vE?qF9I{$0 1.Co-stimulators (or co-stimulating molecules)
l)VMF44 2.NK-kB
`Pl=%DR 3.Immunoglobulin superfamily
#eE:hiu<v 4.antigen-presenting cell (APC)
OR&+`P"-\ 5.death domain
{b/60xl? 6.CCR and CXCR
)'%L#
7.Lectin (or mitogen)
_F^|n}Qbj 8.Clusters of differentiation, CD)
bz H5Lc {% 9.B7 family
$.kIB+K 10.Cytotoxic T lymphocyte, CTL)
>E
"FoZM= 11.IL-15 and IL-15 receptor (IL-15R)
1Sz5&jz 12.MHC restriction
TaM,9MAu 13.Affinity-chromatography
XA9$n_|bw 14.Cyctosprin A, CsA
X+
iA"B 15.Antibody-dependent cell-mediated cytotoxicity, ADCC)
{br4B7b ¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£©
4KybN 1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿
tvRa.3 2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£
$
Qg81mu 3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹ÔµÄÌØµã¡£
5+%BZ Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£©
(a7IxW ÃâÒßѧרҵ£º
1ygu>sKS&A 1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£
6xz&Qi7w Ïû»¯ÄÚ¿Æ£º
|BYD] vK 2.Ö×Áö¿¹Ô·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£
`q_7rrkO ѪҺ²¡Ñ§×¨Òµ£º
P!bm$h*3? 3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔÒò£¨Ìõ¼þ£©ÊÇʲô£¿
z
eIBB Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ
` S85i* (רҵ»ù´¡: ÃâÒßѧ)
qd{|"(9B Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö)
T/S-}|fhQ 1. ADCC(antibody dependent cell-mediated cytotoxicity)
L**!$k"{5 2. »·æß¾úËØ(cyclosporin)
2~]c`/M3 3. KIR(killer cell inhibitory receptor)
$$qhX]^~ 4. HLDA(human leucocyte differentiation antigen)
kf5921(P 5. Interleukin 18(IL-18)
$ /wr? 6. ÕûºÏËØ(integrin)
9pjk3a 7. Fas/FasL
pbm4C0W} 8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå)
Mu:*(P/ 9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM)
,hOJe=u46 10. Th1/Th2
SH}O?d\Q: 11. »ùÒòÒßÃç(DNAÒßÃç)
2EE#60 12. chemokines and chemokine receptor
_&w!JzpXT 13. ÃâÒßÄÍÊÜ
i!cz
I8 14. ¹²´Ì¼¤·Ö×Ó
W
BiBtU 15. ËÀÍö½á¹¹Óò(death domain)
*2@q=R-1 ¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö)
Qgf_ 1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉ˰Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬?
u8[X\f 2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»ÆÆ¶ø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦Óá£
y5R6/*;N. £¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î
d0N7aacY £¨2£©1977Ä꣺·ÅÉäÃâÒß·¨
DTr0u}m £¨3£©1984Ä꣺ÁܰÍϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå
fwl
RwH( £¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹
92} ,A`= 3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄÐ©ÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£
f'%}{l: ss Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(ÃâÒßѧרҵ)
X$st{@}ZB ÎÊ´ðÌâ(ÿÌâ25·Ö)
LTa9'
q0 1. ÊԱȽÏTϸ°ûÊÜÌ壨TCR£©¡¢Bϸ°ûÊÜÌ壨BCR£©ºÍNKϸ°ûÊÜÌ壨NKCR£©µÄ×é³É£¬Ê¶±ðÅäÌåÒÔ¼°ÐźÅתµ¼µÄÒìͬµã¡£
WnIh (
0 2. ÒÔÐØÏÙÒÀÀµ¿¹Ô´Ì¼¤»úÌå²úÉú¿¹ÌåµÄÃâÒßÓ¦´ðΪÀý£¬Tϸ°ûºÍBϸ°ûÊÇÈçºÎÏ໥×÷Óã¿ÓÐÄÄЩճ¸½·Ö×Ӻ͹²´Ì¼¤·Ö×Ó²ÎÓëT¡¢Bϸ°ûµÄÏ໥×÷Óã¿
>)VrbPRuA
3. Éö×ÛºÏÕ÷³öѪÈÈ(HFRS)²¡¶¾µÄ½á¹¹»ùÒòÒѾ¸ãÇå³þ,ΪÁË֤ʵHFRS²¡¶¾¸ÐȾ»úÌå(ÒÔBalb/CСÊóΪÀý)¿É²úÉúHFRS²¡¶¾ºËÒ¿ǵ°°×(NP)ÌØÒìÐÔCTL,²¢ÔÚÃâÒß·À»¤ÖÐÆðÖØÒª×÷ÓÃ,ÇëÓ¦ÓÃÃâÒßѧÀíÂۺͷ½·¨,Éè¼ÆÒ»ÏµÍ³ÊµÑé,¼ÓÒÔ֤ʵ¡£
Y8C
Xinh 4. Àý¾Ù¶þ¸ö½üÄêÀ´Ï¸°ûºÍ·Ö×ÓÃâÒßѧÑо¿ÖгöÏÖµÄеÄÈȵã,Çë·Ö±ðÆÀÊöÆäÑо¿ÒâÒå¡¢·¢Õ¹Ç÷ÊÆÒÔ¼°Ó¦ÓÃǰ¾°¡£